FIRST ON CNN: Fighting early-stage Alzheimer's with intensive lifestyle changes works, study finds
'I honestly thought I was losing my mind, and the fear of losing my mind was frightening,' Maida told CNN Chief Medical Correspondent Dr. Sanjay Gupta in the 2024 CNN documentary 'The Last Alzheimer's Patient.'
After 20 weeks in a randomized clinical trial designed to drastically change her diet, exercise, stress levels and social interactions, Maida's cognition improved. She was able to read and recall novels and correctly balance spreadsheets again. A blood test even found levels of amyloid, a hallmark of Alzheimer's disease, were retreating in her brain, according to the study published in June 2024.
'I'm coming back. It was really good — like I was prior to the disease being diagnosed,' Maida, now 68, told a researcher on the study. 'An older but better version of me.'
Maida's cognition showed additional improvement, however, after she completed a total of 40 weeks of intensive lifestyle changes, said principal investigator Dr. Dean Ornish, a clinical professor of medicine at the University of California, San Francisco, and creator of the Ornish diet and lifestyle medicine program.
Ornish gave a study update on Tuesday at the 2025 Alzheimer's Association International Conference in Toronto.
While not everyone in the 26-person interventional group benefited, 46% showed improvement in three of four standardized tests, he said, including one that measures changes in memory, judgment and problem-solving as well as the ability to function at home, practice hobbies and practice personal hygiene.
'An additional 37.5% of people showed no decline in cognition during those 40 weeks,' Ornish said. 'Thus, over 83% of patients improved or maintained their cognition during the five-month program.'
The new findings mirrored those of other studies on lifestyle interventions, he said, including the recent US POINTER study, the largest clinical trial in the United States to test moderate lifestyle interventions over two years in people who are at risk but do not yet have Alzheimer's disease.
'Our study complements these findings by showing, for the first time, that more intensive lifestyle changes may often stop or even begin to reverse the decline in cognition in many of those who already have Alzheimer's disease, and these improvements often continue over a longer period of time,' Ornish told CNN.
And unlike available medications for Alzheimer's, he added, lifestyle changes have no side effects, such as bleeding and swelling in the brain that may occur with the newest class of drugs.
EmblemHealth, a New York-based insurance company, announced Tuesday that it will be the first health insurer to cover the Ornish lifestyle medicine program for patients who have early-stage Alzheimer's disease.
'Eat well, move more, stress less and love more'
The lifestyle intervention Ornish created — which he calls 'eat well, move more, stress less and love more' — has been tested before. In 1990, Ornish showed for the first time in a randomized clinical trial that coronary artery disease could often be reversed with nothing more than diet, exercise, stress reduction and social support.
The US Centers for Medicare and Medicaid Services, or CMS, declared in 2010 that Ornish's program for reversing heart disease was an 'intensive cardiac rehabilitation' and that it would be eligible for reimbursement under Medicare.
Additional research has shown the same four-part program can lower blood sugars and heart disease risk in patients with diabetes, reduce prostate cancer cell growth, improve depression and even lengthen telomeres, the protective caps of chromosomes that are worn away by aging.
During the Ornish intervention, one group of people consumed a strict vegan diet, did daily aerobic exercise, practiced stress reduction and engaged in online support groups. The rest of the participants were in a control group and were asked to not make any changes in their daily habits.
Therapists led hour-long group sessions three times a week in which participants were encouraged to share their feelings and ask for support. Meditation, deep breathing, yoga and other ways to reduce stress took up another hour every day. The program also encouraged participants to prioritize good-quality sleep.
Supplements were provided to everyone in the intervention group, including a daily multivitamin, omega-3 fatty acids with curcumin, coenzyme Q10, vitamin C and B12, magnesium, a probiotic, and Lion's mane mushroom.
In addition to online strength training led by a physical trainer, people in the intervention attended hour-long video classes on vegan nutrition hosted by a dietitian. Then, to ensure a vegan diet was followed, all meals and snacks for both participants and their partners were delivered to their homes.
Complex carbs found in whole grains, vegetables, fruits, tofu, nuts and seeds made up most of the diet. Sugar, alcohol and refined carbs found in processed and ultraprocessed foods were taboo. While calories were unrestricted, protein and total fat made up only some 18% of the daily caloric intake — far less than the typical protein intake by the average American, Ornish said.
Working harder pays off
People in the intervention group who put the most effort into changing their lifestyle have the most improvement in their cognition, said Ornish, founder and president of the nonprofit Preventive Medicine Research Institute and coauthor of 'Undo It! How Simple Lifestyle Changes Can Reverse Most Chronic Diseases.'
'There was a statistically significant dose-response relationship between the degree of adherence to our lifestyle changes and the degree of improvement we saw on measures of cognition,' Ornish said.
The 25 people in the study's original 20-week control group — who did not receive the intervention — had shown further cognitive decline during the program. They were later allowed to join the intervention for 40 weeks and significantly improved their cognitive scores during that time, Ornish said.
It all makes sense, said co-senior study author Rudy Tanzi, an Alzheimer's researcher and professor of neurology at Harvard Medical School in Boston.
'If you picture a brain full of damage as a sink full of water, when you just turn off the tap, it takes a long time for that sink to slowly drain, right?' Tanzi told CNN in 2024. 'If you want the amyloid to go down in 20 weeks, as we found on one blood test, you're going to need a Roto-Rooter.'
Additional blood testing may offer insights
In the 2024 study, a blood test called plasma Aβ42/40 showed a significant improvement in the original intervention group. Aβ42/40 measures the level of amyloid in the blood, a key symptom of Alzheimer's.
Tests that measure amyloid in different ways, however, did not show improvement, Dr. Suzanne Schindler, an associate professor of neurology at Washington University School of Medicine in St. Louis who specializes in blood biomarkers told CNN at the time.
There was no significant change in a test for amyloid called p-tau 181, considered to be a superior measure of Alzheimer's risk, said Schindler, who was not involved in the study. Nor was there any change in glial fibrillary acidic protein, or GFAP, another blood biomarker that seems to correlate reasonably well with Alzheimer's disease.
'If one of these markers improves, you typically see all of them improve, so the fact they did not makes me wonder whether this effect is real,' Schindler said. 'If they were to repeat the study with a much larger population for a longer period of time, perhaps more change could be seen.'
Over the complete 40-week program, however, a number of people in the intervention group did continue to improve their Aβ42/40 scores, according to the study update.
'Changes in amyloid — as measured as the plasma Aβ42/40 ratio — occur before changes in tau markers such as p-tau 218, so this is not surprising after only 40 weeks,' Ornish said.
For Ornish, who has watched members of his family die from Alzheimer's disease, the study's results are important for one key reason — hope.
'So often when people get a diagnosis of dementia or Alzheimer's, they are told by their doctors that there is no future, 'It's only going to get worse, get your affairs in order.' That's horrible news and is almost self-fulfilling,' Ornish said.
'Our new findings empower patients who have early-stage Alzheimer's disease with the knowledge that if they make and maintain these intensive lifestyle changes, there is a reasonably good chance that they may slow the progression of the disease and often even improve it,' he said.
'Our study needs to be replicated with larger, more diverse groups of patients to make it more generalizable,' Ornish said. 'But the findings we reported today are giving many people new hope and new choices — and the only side effects are good ones.'
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Revenue: $545 million, a 73% year-over-year increase. Adjusted EBITDA Margin: Over 15%. Subscribers: Increased by 73,000 quarter over quarter to over 2.4 million, a 31% year-over-year growth rate. Monthly Average Revenue per Subscriber: Declined quarter over quarter to $74 from $84. Gross Margin: Expanded 3 points quarter over quarter to 76%. Cash and Short-term Investments: Over $1.1 billion at the end of the second quarter. Free Cash Flow: Negative $69 million for the second quarter. Third Quarter Revenue Guidance: Expected between $570 million to $590 million. Full Year Revenue Guidance: Expected between $2.3 billion and $2.4 billion. Full Year Adjusted EBITDA Guidance: Expected between $295 million to $335 million. Warning! GuruFocus has detected 5 Warning Sign with HIMS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hims & Hers Health Inc (NYSE:HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%. The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women. Hims & Hers Health Inc (NYSE:HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada. The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement. Hims & Hers Health Inc (NYSE:HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management. Negative Points The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition. There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term. Hims & Hers Health Inc (NYSE:HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital. The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines. The company anticipates increased marketing and technology investments, which may pressure margins in the near term. Q & A Highlights Q: Why was now the right time to expand internationally, and what made ZAVA the right company to acquire? A: Andrew Dudum, CEO, explained that the acquisition of ZAVA is a strategic move to replicate Hims & Hers' personalized, high-touch, affordable precision medicine model in key international markets. ZAVA's ability to scale in unique regulatory environments was a key factor in the acquisition. The international market is seen as a focused effort, with a multibillion-dollar revenue opportunity in a few key markets. Q: How does the launch of at-home lab testing improve the business and support the broader mission of Hims & Hers? A: Andrew Dudum, CEO, emphasized that at-home lab testing is foundational for transitioning healthcare from treatment to prevention. It simplifies necessary tests, makes them affordable, and educates patients on optimal health metrics. This initiative is expected to open membership opportunities similar to Amazon or Costco, focusing on preventative health. Q: Can you provide insights into the core business dynamics and expectations for Q3, especially regarding the personalized GLP-1 offering? A: Oluyemi Okupe, CFO, noted material headwinds in the GLP-1 segment due to off-boarding commercially available dosages. The core business is experiencing a drag from the sexual health on-demand segment, but specialties like dermatology and weight loss are growing robustly. The transition to daily offerings in sexual health is expected to improve retention and customer lifetime value. Q: What are the expectations for the Canadian expansion and the impact of generic semaglutide pricing? A: Andrew Dudum, CEO, stated that the Canadian expansion will leverage ZAVA's expertise, with offerings under the Hims & Hers brand. The generic semaglutide is expected to be priced significantly lower than branded options, unlocking substantial market access in Canada, where a large portion of the population is affected by weight issues. Q: How is the Hers business performing, and what are the key growth drivers? A: Oluyemi Okupe, CFO, reported robust growth in the Hers business, driven by dermatology, weight loss, and mental health offerings. The upcoming launch of hormonal support for menopause is expected to further catalyze growth. Q: What is the approach to AI investments, and what impact is expected on the business? A: Andrew Dudum, CEO, highlighted a strategy focused on immediate, tactical improvements through AI. The platform's extensive patient interactions allow for rapid deployment of AI use cases, aiming to enhance efficiency and engagement across the provider, patient, and pharmacist interfaces within 3 to 6 months. Q: Can you discuss the marketing strategy and patient acquisition costs for the second half of the year? A: Oluyemi Okupe, CFO, stated that marketing investments will be robust but adhere to a capital allocation framework with a payback period of less than a year. The focus will be on specialty-specific investments and talent acquisition to support new specialties and international expansion. Q: What are the expectations for inventory levels and supply chain management? A: Oluyemi Okupe, CFO, explained that inventory levels increased to ensure a durable supply for new specialties and to leverage the strong balance sheet amid global uncertainties. This is seen as an anomaly, with future inventory adjustments expected to stabilize. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
‘In limbo': Mum's shock diagnosis at 29
Erin Kelly is likely going to forget her eight-year-old daughter Evie's name before her little girl finishes high school. At just 29 years old, the Queensland mum has been diagnosed with a rare hereditary form of Alzheimer's disease. It is the most common form of dementia in Australia – making up 70 per cent of all cases – and is a condition most people develop in their mid- to late-60s. In January 2020, Ms Kelly's father revealed that she and her siblings had a 50/50 chance of getting Alzheimer's – information she decided to 'pretend (she) was never told'. 'Originally I think I was in a little bit of denial, and I originally said I didn't want to know,' Ms Kelly said. 'I sort of stuck my head in the sand and just pretended it wasn't happening for probably the first three years, until I decided that I needed to do something about it.' Ms Kelly wasn't even half the standard age of diagnosis when her brain scans came back positive for the gene in May last year. 'I got the results saying that I've inherited the gene, and there wasn't much help from there,' Ms Kelly. 'I'd contacted Alzheimer's Australia and they just said 'Look, we can't help you at the moment. We don't really know who can'. 'I went to a few doctors, a few neurologists – I'd contacted a few people, (but) no one could really help until I got hold of a geriatrician.' Geriatricians are doctors who specialise in multidisciplinary care for the elderly, which can often include managing several chronic conditions, preventing disease, and general quality-of-life care. 'I saw him for a few visits. He ordered the scans, and then it was only a couple of weeks ago that the scan results came back saying there's evidence of disease in the brain already,' Ms Kelly said. 'From what my doctor was saying, my case is very unique – he's never worked with anyone even close to my age,' she said. 'It was very daunting … very conflicting.' Ms Kelly said she often had moments of 'hypervigilance', where she would forget something the way a normal person would and assume the disease had taken hold even earlier than expected. But it was not long before Ms Kelly sprung into action. 'It was, 'All right, well it's not just me (I have to look after) – I've got a child, my brothers, I have cousins … I want to do something about this, there's not enough knowledge out there, it took so long for me to just even be seen,' she said. With the help of her stepsister Jessica Simpson, Ms Kelly has now launched an online fundraiser, which she hopes will both cover her treatment and raise awareness and research funds for unique genetic dispositions that can lead to Alzheimer's. Ms Kelly's geriatrician told her the treatment that could best hold off any degradation in her brain function was 'lecanemab' – but getting a hold of it would not be straightforward. Lecanemab is not approved by the Therapeutic Goods Administration (TGA), and therefore is not subsidised. Eighteen-month treatments currently cost about $90,000, and have not been tested on someone as young as Ms Kelly. 'The criteria at the moment to get any help is (being) 50 to 90 years old,' she said. 'I could go on the drug and it might have a reverse side-effect, but they don't know, so I'm willing to be that person to say, 'All right, let's give it a go and see'.' 'I just want to make a difference for people like me.' Ms Simpson said her stepsister did not give herself enough credit for the effort she is making – not just for herself, but for her family as well. 'She's a great mum to Evie, and I think in general she's just a really easy person to be around,' Ms Simpson said. 'Erin isn't asking for a miracle – she knows there's no cure … she's simply asking for more time. More ordinary days. More little moments. More memories Evie can carry with her when Erin no longer can.' 'If you can help … your support means the world to our family.' About 480,000 Australians currently live with dementia, according to Alzheimer's Research Australia.
Yahoo
an hour ago
- Yahoo
Taking This Supplement Daily Could Add 5 Years to Your Life, Biochemist Says
Taking This Supplement Daily Could Add 5 Years to Your Life, Biochemist Says originally appeared on Men's Fitness. Longevity is a trending topic these days, with people turning to all kinds of products and gimmicks to try and extend their lifespan. But Biochemist Rhonda Patrick just revealed a simple, science-backed solution that could add five years to your life: omega-3's. Omega-3s are fatty acids that play a key role in brain function, heart health, and reducing inflammation throughout the body. They're found primarily in fatty fish like salmon and mackerel, and can be supplemented with fish oil and certain plant sources like flaxseed. An optimal omega-3 index is around 8 percent, but the U.S. average hovers below 5 percent. That difference could translate to a five-year increase in life expectancy."Studies have been done and it takes about on average 2 grams of omega-3 supplementation a day to go from 4 percent to 8 percent," Patrick says. "People that have the 8 percent omega-3 index have a five year increased life expectancy compared to people that have 4 percent." To raise your omega-3 index, consider supplementing with high-quality fish oil or eating fatty fish like salmon regularly. The benefits don't stop there. High omega-3 intake is also associated with better brain health, lower inflammation, reduced risk of Alzheimer's, and even protection against muscle loss. "There's studies showing that you're much less likely to get Alzheimer's disease if you have a high omega-3 index. The quality of life is better," Patrick says. One study even found that smokers with high omega-3 levels live as long as non-smokers with low omega-3 levels. "I think omega-3 has the pharmacological potential to act like drugs but the safety profile of a nutrient," Patrick This Supplement Daily Could Add 5 Years to Your Life, Biochemist Says first appeared on Men's Fitness on Jul 10, 2025 This story was originally reported by Men's Fitness on Jul 10, 2025, where it first appeared. Solve the daily Crossword